rss
Thorax 2000;55:260-265 doi:10.1136/thorax.55.4.260
  • Original article

Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients

  1. R J Dockhornc,
  2. R A Baumgartnerb,
  3. J A Leffb,
  4. M Noonand,
  5. K Vandormaela,
  6. W Strickere,
  7. D E Weinlandb,
  8. T F Reissb
  1. aMerck Research, MSD, Brussels, Belgium, bMerck Research Laboratories, Rahway, New Jersey, USA, cInternational Medical and Technical Consultants Inc, Lenexa, Kansas, USA, dAllergy Associates, PC Research Center, Portland, Oregon, USA, eClinical Research of the Ozarks Inc, Columbia, Missouri, USA
  1. Dr T F Reiss, Merck Research Laboratories, RY 32-648, Rahway, New Jersey 07065-1900, USA
  • Received 24 March 1999
  • Revision requested 24 May 1999
  • Revised 10 June 1999
  • Accepted 13 July 1999

Abstract

BACKGROUND Montelukast, a leukotriene receptor antagonist, improves parameters of asthma control including forced expiratory volume in one second (FEV1) when given orally to patients aged six years or older. This study was undertaken to compare the effect on FEV1 of intravenous and oral montelukast and placebo during the 24 hour period following administration.

METHODS Fifty one asthmatic patients (FEV1 40–80% predicted and≥15% improvement after inhaled β agonist) were enrolled in a double blind, single dose, three period, crossover study to receive intravenous montelukast (7 mg), oral montelukast (10 mg), or placebo in a randomised fashion. The primary end point was area under the curve (AUC)0–24 h of the percentage change from baseline in FEV1. Additional end points were maximum percentage change in FEV1 and percentage change at different time points.

RESULTS Compared with placebo, intravenous and oral montelukast significantly increased the AUC0–24 h (means of 20.70%, 15.72%, and 7.75% for intravenous, oral and placebo, respectively; no statistical difference between intravenous and oral). The difference in least square means from placebo for intravenous montelukast was 13.27% (95% CI 7.07 to 19.46), p<0.001 and for oral montelukast was 7.44% (95% CI 1.20 to 13.68), p = 0.020. The maximum percentage change in FEV1was not significantly different for intravenous and oral montelukast (difference in least square means 6.78% (95% CI –0.59 to 14.15), p = 0.071). The mean percentage change in FEV1 for intravenous montelukast was greater than for oral montelukast within the first hour (15.02% vs 4.67% at 15 min, p≤0.001; 18.43% vs 12.90% at one hour, p<0.001 for intravenous and oral montelukast, respectively (placebo 3.05% at 15 minutes, 7.33% at one hour). Intravenous and oral montelukast were similar to placebo in the frequency of adverse events.

CONCLUSIONS The onset of action for intravenous montelukast was faster than for oral montelukast and the improvement in airway function lasted over the 24 hour observation period for both treatments. Although not well understood, there was a trend toward a greater improvement in FEV1 with intravenous than with oral montelukast. These findings suggest that leukotriene receptor antagonists should be investigated as a treatment for acute severe asthma.

Footnotes

  • Source of funding: Merck Research Laboratories.

This Article

  1. Abstract
  2. Full text
  3. PDF

Register for free content


Free trial
Individuals may register for a free 30 day online trial to all content.

Free archive
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.